|
Bioms Medical secures long-term manufacturing agreements for multiple sclerosis drug |
|
|
|
15 Feb 2006 |
EDMONTON, Canada | Feb 15, 2006 | BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that it has secured long-term manufacturing agreements with two global companies, UCB-Bioproducts and Hospira Worldwide Inc., for its lead MS drug MBP8298.
Under the terms of the agreements, UCB-Bioproducts will continue to manufacture the MBP8298 bulk drug and Hospira will fill and finish the drug product into vials for use in patients. These contracts contemplate these companies providing their services through the current pivotal clinical trial for MBP8298 and into commercial production.
“These agreements emphasize our commitment to bring a quality, first-in-class therapeutic to MS patients and are important to the success of the anticipated future launch of MBP8298 into the marketplace,” said Kevin Giese, President of BioMS Medical. “Both UCB and Hospira are public companies, world-leaders in quality manufacturing and recognized experts in their field of work.”
About UCB
With more than 30 years of experience dedicated to peptide API contract manufacturing, UCB-Bioproducts is the world-leader in pharmaceutical peptides and peptidomimetics’, supporting customers’ projects with services from preclinical to commercialization through clinical development. UCB-Bioproducts is a division of UCB, a global biopharmaceutical leader headquartered in Brussels, Belgium, with manufacturing facilities in Europe, US and Sales and Marketing offices in Europe, US and Japan. UCB employs over 8,500 people operating in over 40 countries worldwide. More information is available on www.ucb-bioproducts.com.
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical’s lead technology, MBP8298, is for the treatment of multiple sclerosis and is currently in a pivotal phase II/III clinical trial across Canada and Europe. For further information please visit our website at www.biomsmedical.com.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of BioMS Medical with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
SOURCE: BioMS Medical Corp. |
